FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA NephropathyPRNewsWire • 12/15/21
Calliditas Therapeutics Stock Falls As FDA Pushes Nefecon PDUFA Goal Date To DecemberBenzinga • 09/15/21
Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 millionPRNewsWire • 08/12/21
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in EuropePRNewsWire • 07/21/21
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines AgencyPRNewsWire • 05/28/21
Calliditas Therapeutics AB (CALT) CEO Renée Lucander on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/18/21
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021PRNewsWire • 05/14/21